Alterity Therapeutics Limited
NASDAQ:ATHEBiotechnology
+$0.53 today
- Market cap
- $52.77M
- Beta
- -0.03
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.07
Volume 0.02M
Average 0.05M
ATHE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Alterity Therapeutics LimitedNASDAQ: ATHE
Research & Development · Q2 FY2026 · quarter ended Dec 2025
Research & development grows 34.6% year over year
Q2 FY2026 research & development of A$7.7M rose 34.6% year over year. Over 3 fiscal years it compounded at -0.8% a year.
Context
- Research & development amounted to 264.8% of revenue in FY2025, down 199.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
AUD · from the income statement
- Latest · FY2025
- 14.4M AUD
- Year-over-year change
- -22.7%
- 4-year CAGR
- +4.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 14.4M | -22.7% |
| FY2024 | 2024-06-30 | 18.64M | +41.3% |
| FY2023 | 2023-06-30 | 13.2M | -10.5% |
| FY2022 | 2022-06-30 | 14.75M | +20.0% |
| FY2021 | 2021-06-30 | 12.28M | — |
Research & Development vs competitors
How ATHE compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.7% is the lowest of 4, against a peer median of +36.6%.
- Research & development amounts to 264.8% of revenue for ATHE, versus a peer median of 64.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B USD | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $14.87M USD | +36.6% | +1076.5% | — | |
| FY2025 | A$14.4M AUD | -22.7% | -0.8% | 264.8% | |
| LTM Mar 2026 | $1.91M USD | -5.1% | -21.8% | 64.3% | |
| Peer median (excluding ATHE) | — | +36.6% | +15.1% | 64.3% | |
Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M |
| Cost of Revenue | 360.03K | 364.67K | 285.07K | 214.3K | 127.52K |
| Gross Profit | 3.98M | 4.76M | 3.63M | 3.8M | 5.31M |
| Gross Margin | 91.7% | 92.9% | 92.7% | 94.7% | 97.7% |
| Research & Development | 12.28M | 14.75M | 13.2M | 18.64M | 14.4M |
| Selling, General & Admin | 6.87M | 5.51M | 5.04M | 4.76M | 5.48M |
| Operating Expenses | 19.16M | 20.26M | 18.24M | 23.41M | 19.89M |
| Depreciation & Amortization | 18.66K | 54.21K | 37.85K | 35.34K | 28.31K |
| EBITDA | (15.16M) | (17.39M) | (14.6M) | (19.57M) | (14.63M) |
| EBITDA Margin | -349.3% | -339.5% | -372.8% | -486.9% | -269.0% |
| Operating Income | (15.18M) | (15.5M) | (14.64M) | (19.6M) | (14.57M) |
| Operating Margin | -349.8% | -302.6% | -373.7% | -487.7% | -268.0% |
| Interest Income | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (133.04K) | 2.72M | 904.68K | 524.33K | 2.49M |
| Income Before Tax | (15.31M) | (12.78M) | (13.7M) | (19.08M) | (12.08M) |
| Pre-Tax Margin | -352.8% | -249.4% | -349.9% | -474.6% | -222.1% |
| Income Tax Expense | (3.08M) | 70.01K | 104.46K | 46.09K | 68.06K |
| Net Income | (15.31M) | (12.85M) | (13.81M) | (19.12M) | (12.15M) |
| Net Margin | -352.8% | -250.7% | -352.5% | -475.8% | -223.4% |
| EPS (Basic) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| EPS (Diluted) | (5.40) | (3.18) | (3.42) | (3.12) | (1.14) |
| Weighted Avg Shares | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Weighted Avg Shares (Diluted) | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
Alterity Therapeutics Limited
NASDAQ:ATHE
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.